171 related articles for article (PubMed ID: 22493388)
1. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.
Nagai Y; Toita T; Wakayama A; Nakamoto T; Ooyama T; Tokura A; Inamine M; Kudaka W; Murayama S; Aoki Y
Anticancer Res; 2012 Apr; 32(4):1475-9. PubMed ID: 22493388
[TBL] [Abstract][Full Text] [Related]
2. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B
Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma.
Tang J; Tang Y; Yang J; Huang S
Gynecol Oncol; 2012 May; 125(2):297-302. PubMed ID: 22307061
[TBL] [Abstract][Full Text] [Related]
4. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
Hosaka M; Watari H; Kato T; Odagiri T; Konno Y; Endo D; Mitamura T; Kikawa S; Suzuki Y; Sakuragi N
J Surg Oncol; 2012 May; 105(6):612-6. PubMed ID: 22065519
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Hsueh S; Chen CK; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):429-36. PubMed ID: 20542643
[TBL] [Abstract][Full Text] [Related]
8. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.
Song S; Song C; Kim HJ; Wu HG; Kim JH; Park NH; Song YS; Kim JW; Kang SB; Ha SW
Gynecol Oncol; 2012 Jan; 124(1):63-7. PubMed ID: 22004904
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.
Katanyoo K; Sanguanrungsirikul S; Manusirivithaya S
Gynecol Oncol; 2012 May; 125(2):292-6. PubMed ID: 22293041
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
Yoon MS; Chung WK; Ahn SJ; Nam TK; Nah BS; Song JY; Lim SC; Lee JK
Acta Otolaryngol; 2008 May; 128(5):590-6. PubMed ID: 18421617
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
Zhang MQ; Liu SP; Wang XE
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):821-7. PubMed ID: 20207507
[TBL] [Abstract][Full Text] [Related]
12. [Retrospective study of chemoradiotherapy based on cisplatin compared with radiotherapy alone for cervical cancer].
Han C; Kong WM
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):723-6. PubMed ID: 18307894
[TBL] [Abstract][Full Text] [Related]
13. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
[TBL] [Abstract][Full Text] [Related]
14. Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer.
Kawase S; Okuda T; Ikeda M; Ishihara S; Itoh Y; Yanagawa S; Ishigaki T
Gynecol Oncol; 2006 Sep; 102(3):493-9. PubMed ID: 16478629
[TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.
Arakaki Y; Ariga T; Heianna J; Shimoji Y; Nakasone T; Taira Y; Nakamoto T; Ooyama T; Kudaka W; Kaneshima I; Nishihira K; Mekaru K; Aoki Y
In Vivo; 2020; 34(5):2739-2743. PubMed ID: 32871808
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
17. A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.
Choi CH; Lee YY; Kim MK; Kim TJ; Lee JW; Nam HR; Huh SJ; Lee JH; Bae DS; Kim BG
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1252-7. PubMed ID: 21075554
[TBL] [Abstract][Full Text] [Related]
18. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
Torres MA; Jhingran A; Thames HD; Levenback CF; Bodurka DC; Ramondetta LM; Eifel PJ
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):118-25. PubMed ID: 17869451
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
20. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
